Viracta Therapeutics, Inc. to Post Q1 2023 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:VIRX)

Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) – Equities research analysts at HC Wainwright increased their Q1 2023 earnings per share (EPS) estimates for shares of Viracta Therapeutics in a research note issued to investors on Tuesday, March 14th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.31) per share for the quarter, up from their prior estimate of ($0.34). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for Viracta Therapeutics’ Q2 2023 earnings at ($0.31) EPS, Q3 2023 earnings at ($0.32) EPS, Q4 2023 earnings at ($0.32) EPS and FY2023 earnings at ($1.25) EPS.

Separately, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Viracta Therapeutics in a report on Tuesday.

Viracta Therapeutics Stock Performance

Shares of Viracta Therapeutics stock opened at $1.65 on Thursday. The business’s fifty day simple moving average is $1.91 and its 200 day simple moving average is $2.82. The company has a current ratio of 8.49, a quick ratio of 8.49 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $63.03 million, a P/E ratio of -1.27 and a beta of 1.33. Viracta Therapeutics has a 12 month low of $1.21 and a 12 month high of $5.75.

Institutional Trading of Viracta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP bought a new position in shares of Viracta Therapeutics during the third quarter worth $4,248,000. Laurion Capital Management LP bought a new stake in Viracta Therapeutics during the second quarter valued at about $2,708,000. Millennium Management LLC purchased a new position in Viracta Therapeutics in the second quarter valued at about $1,227,000. Vanguard Group Inc. lifted its position in shares of Viracta Therapeutics by 22.8% during the third quarter. Vanguard Group Inc. now owns 1,114,368 shares of the company’s stock valued at $4,759,000 after buying an additional 207,108 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Viracta Therapeutics during the 3rd quarter worth approximately $625,000. 32.35% of the stock is owned by hedge funds and other institutional investors.

Viracta Therapeutics Company Profile

(Get Rating)

Viracta Therapeutics, Inc a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.